Benefits of respiratory treatment for extremely premature infants persist

NewsGuard 100/100 Score

By Piriya Mahendra, medwireNews Reporter

There are no significant differences in death or neurodevelopmental impairment between toddlers who underwent early continuous positive airway pressure (CPAP) or early surfactant administration as extremely premature infants, research shows.

Moreover, there was no difference in the composite outcome of neurodevelopmental impairment and death according to whether infants had a low or high target range of oxygen saturation, report Neil Finer (University of California, San Diego, USA) and colleagues.

"This is the first study to compare surfactant treatment to CPAP in a large group of infants, and these results reassure us that CPAP is as good a choice in the first hour of life as traditional methods for very preterm babies who need help breathing," commented co-author Rosemary Higgins (Eunice Kennedy Shriver National Institute of Child Health and Human Development, Rockville, Maryland, USA) in a press statement.

The follow-up study extends earlier findings that showed infants born aged 24-27 weeks gestation were more likely to survive if they received higher oxygen levels, although they were also at an increased risk for severe retinopathy. The 2010 study also demonstrated that CPAP was as effective as standard therapy with a ventilator and surfactant administration.

All infants were either randomly assigned to early CPAP with a limited ventilation strategy or early surfactant administration and to lower or higher target ranges of oxygen saturation (85-89% or 91-95%).

The current study followed the infants at 18-22 months for the primary composite outcome of death before assessment or neurodevelopmental impairment.

As reported in the NEJM, the researchers determined the primary outcome in 1234 (93.8%) of 1316 enrolled infants; 990 (93.6%) of the 1058 surviving infants were evaluated at 18-22 months of corrected age.

Death or neurodevelopmental impairment occurred in 27.9% of those in the CPAP group, compared with 29.9% of those in the surfactant group, corresponding to a nonsignificant relative risk of 0.93.

Death or neurodevelopmental impairment also occurred in 30.2% of infants in the lower oxygen group versus 27.5% of those in the higher oxygen saturation group, corresponding to a nonsignificant relative risk of 1.12.

Mortality was significantly higher in infants with the lower oxygen saturation target than in those with a higher one, at 22.1% versus 18.2%, corresponding to a relative risk of 1.25.

"Although these findings can give delivery room practitioners confidence in a suitable approach, they can't help predict how these children will grow or how well they'll do in school," remarked Higgins. "Our group will continue to monitor the health of a subset of these children through childhood, to determine if there are any major differences between the groups."

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Comments

  1. Dale Dearing Dale Dearing United States says:

    Research confirms clinical practices we know work.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Impact of nirsevimab immunization on pediatric RSV-related hospitalizations in Luxembourg